CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 400 enrolled
Drug / intervention
Aspirin +1 moredrug
Likely dose
Aspirin 325mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01504867
NCT01504867Phase 2Completed
CompareCT.gov

LIPS-A: Lung Injury Prevention Study With Aspirin

Mayo Clinic·interventional·Posted Jan 6, 2012·Updated Mar 6, 2017

In Brief

A Phase 2 clinical trial evaluating Aspirin and Lactose powder for Acute Respiratory Distress Syndrome. Completed, enrolled 400 participants across 16 sites.

Detailed Summary

The primary hypothesis was that early aspirin administration will decrease the rate of developing acute lung injury during the first 7 days after presentation to the hospital.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Respiratory Distress Syndrome
CountriesUnited States
CollaboratorsBeth Israel Deaconess Medical Center, Montefiore Medical Center, Vanderbilt University Medical Center, National Heart, Lung, and Blood Institute (NHLBI), National Center for Research Resources (NCRR)

Timeline

Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedJan 6, 2012
Enrollment StartJan 1, 2012
Primary CompletionSep 1, 2015
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 14.5 years ago

Interventions

Aspirindrug

325mg loading dose once on study day 1, followed by 81mg dose once daily on study days 2-7. Administered by mouth or down nasal gastric tube.

Lactose powderdrug

Matching lactose powder filled capsules will be administered on days 1-7.